Partially-desulfated heparin improves survival in Pseudomonas pneumonia by enhancing bacterial clearance and ameliorating lung injury

References

• Abraham, E., Arcaroli, J., Carmody, A., et al. 2000. Cutting edge: HMG-1 as a mediator of acute lung inflammation. J. Immunol. 165:2950–2954
   PubMed Web of Science ®Google Scholar
• American Thoracic Society and Infectious Diseases Society of America. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Resp. Crit. Care Med. 171:388–416
   PubMed Web of Science ®Google Scholar
• Berra, L., Sampson, J., and Wiener-Kronish, J. 2010. Pseudomonas aeruginosa: Acute lung injury or ventilator-associated pneumonia? Minerva Anestesiol. 76:824–832
   PubMed Web of Science ®Google Scholar
• Carr, J. 1979. The anti-inflammatory action of heparin: Heparin as an antagonist to histamine, bradykinin, and prostaglandin. Thrombosis Res. 16:507–516
   PubMed Web of Science ®Google Scholar
• Chaudhuri, N., and Sabroe, I. 2008. Basic science of the innate immune system and the lung. Paed. Resp. Rev. 9:236–242
   Google Scholar
• Dixon, B., Schultz, M. J., Smith, R., et al. 2010. Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: A randomized controlled trial. Crit. Care. 14:R180
   Web of Science ®Google Scholar
• El Solh, A. A., and Alhajhusain, A. 2009. Update on the treatment of Pseudomonas aeruginosa pneumonia. J. Antimicrob. Chemother. 64:229–238
   PubMed Web of Science ®Google Scholar
• Entezari, M., Weiss, D. J., Sitapara, R., et al. 2012. Inhibition of HMGB1 enhances bacterial clearance and protects against P. aeruginosa pneumonia in cystic fibrosis. Mol. Med. 18:477–485
   PubMed Web of Science ®Google Scholar
• Etminan, M., Forooghian, F., Brophy, J. M., et al. 2012. Oral fluoro-quinolones and the risk of retinal detachment. JAMA 307:1414–1419
   PubMed Web of Science ®Google Scholar
• Ferrara, A. M. 2006. Potentially multidrug-resistant non-fermentative Gram-negative pathogens causing nosocomial pneumonia. Int. J. Antimicrob. Agents. 27:183–195
   PubMed Web of Science ®Google Scholar
• Flanders, S. A., Collard, H. R., and Saint, S. 2006. Nosocomial pneumonia: State of the science. Am. J. Infect. Control. 34:84–93
   PubMed Web of Science ®Google Scholar
• Fryer, A., Huang, Y. C., Rao, G., et al. 1997. Selective O-desulfation produces non-anti-coagulant heparin that retains pharmacological activity in the lung. J. Pharmacol. Exp. Ther. 282:208–219
   PubMed Web of Science ®Google Scholar
• Govan, J., and Deretic, V. 1996. Microbial pathogenesis in cystic fibrosis: Mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol. Rev. 60:539–574
   PubMedGoogle Scholar
• Halbertsma, F., Vaneker, M., Scheffer, G., and van der Hoeven, J. 2005. Cytokines and biotrauma in ventilator-induced lung injury: A critical review of the literature. Neth. J. Med. 63:382–392
   PubMed Web of Science ®Google Scholar
• Heijerman, H. 2005. Infection and inflammation in cystic fibrosis: A short review. J. Cystic Fibrosis. 4:3–5
   PubMedGoogle Scholar
• Hochart, H., Vincent Jenkins, P., Smith, O. P., and White, B. 2006. Low-molecular weight and unfractionated heparins induce a down-regulation of inflammation: Decreased levels of pro-inflammatory cytokines and NF-κB in LPS-stimulated human monocytes. Br. J. Hematol. 133:62–67
   PubMed Web of Science ®Google Scholar
• Hreggvidsdottir, H. S., Östberg, T., Wähämaa, H., et al. 2009. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J. Leukocyte Biol. 86:655–662
   PubMed Web of Science ®Google Scholar
• Jones, R. N. 2010. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin. Infect. Dis. 51:S81–87
   PubMed Web of Science ®Google Scholar
• Lakshmi, T. S., Shanmugasundaram, N., Shanmuganathan, S., and Babu, M. 2011. Efficacy of desulfated heparin mitigating inflammation in rat burn wound model. J. Biomed. Materials Res. 97:215–223
   Google Scholar
• Ling, Y., Yang, Z. Y., Yin, T., et al. 2011. Heparin changes the conformation of high-mobility group protein 1 and decreases its affinity toward receptor for advanced glycation endproducts in vitro. Int. Immunopharmacol. 11:187–193
   PubMed Web of Science ®Google Scholar
• Liu, G., Wang, J., Park, Y. J., et al. 2008. High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J. Immunol. 181:4240–4246
   PubMed Web of Science ®Google Scholar
• Livermore, D. M. 2002. Multiple mechanisms of anti-microbial resistance in Pseudomonas aeruginosa: Our worst nightmare? Clin. Infect. Dis. 34:634–640
   PubMed Web of Science ®Google Scholar
• Lotze, M. T., and Tracey, K. J. 2005. High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5:331–342
   PubMed Web of Science ®Google Scholar
• Lyczak, J. B., Cannon, C. L., and Pier, G. B. 2000. Establishment of Pseudomonas aeruginosa infection: Lessons from a versatile opportunist. Microbes Infect. 2:1051–1060
   PubMed Web of Science ®Google Scholar
• Patel, V. S., Sitapara, R. A., Gore, A., et al. 2013. HMGB1 mediates hyperoxia-induced impairment of Pseudomonas aeruginosa clearance and inflammatory lung injury in mice. Am. J. Respir. Cell Mol. Biol. 48:280–287
   PubMed Web of Science ®Google Scholar
• Rao, N. V., Argyle, B., Xu, X., et al. 2010. Low anti-coagulant heparin targets multiple sites of inflammation, suppresses heparin-induced throm-bocytopenia, and inhibits interaction of RAGE with its ligands. Am. J. Physiol. 299:C97–110
   PubMed Web of Science ®Google Scholar
• Rosenthal, V. D., Bijie, H., Maki, D. G., et al. 2011. International Nosocomial Infection Control Consortium (INICC) report: Data summary of 36 countries, for 2004-2009. Am. J. Infect. Control. 40:396–407
   PubMed Web of Science ®Google Scholar
• Rowe, S. M., Jackson, P. L., Liu, G., et al. 2008. Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am. J. Resp. Crit. Care Med. 178:822–831
   PubMed Web of Science ®Google Scholar
• Sadikot, R. T., Blackwell, T. S., Christman, J. W., and Prince, A. S. 2005. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am. J. Resp. Crit. Care Med. 171:1209–1223
   PubMed Web of Science ®Google Scholar
• Sha, Y., Zmijewski, J., Xu, Z., and Abraham, E. 2008. HMGB1 develops enhanced pro-inflammatory activity by binding to cytokines. J. Immunol. 180:2531–2537
   PubMed Web of Science ®Google Scholar
• Smith, J. A. 1994. Neutrophils, host defense, and inflammation: A double-edged sword. J. Leukocyte Biol. 56:672–686
   PubMed Web of Science ®Google Scholar
• Stover, C. K., Pham, X. Q., Erwin, A. L., et al. 2000. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406:959–964
   PubMed Web of Science ®Google Scholar
• Suntres, Z. E., Omri, A., and Shek, P. N. 2002. Pseudomonas aeruginosa-induced lung injury: Role of oxidative stress. Microb. Pathogen. 32:27–34
   PubMed Web of Science ®Google Scholar
• Torres, A., and Rello, J. 2010. Update on community-acquired and nosocomial pneumonia. 2009. Am. J. Resp. Crit. Care Med. 181:782–787
   Google Scholar
• van Zoelen, M. A., Laterre, P., van Veen, S. Q., et al. 2007. Systemic and local high mobility group box 1 concentrations during severe infection. Crit. Care Med. 35:2799–2804
   PubMed Web of Science ®Google Scholar
• Young, E. 2008. The anti-inflammatory effects of heparin and related compounds. Thrombosis Res. 122:743–752
   PubMed Web of Science ®Google Scholar